Bedaquiline resistance-associated genetic mutations and minimum inhibitory concentrations in drug-resistant tuberculosis clinical isolates from Limpopo province, South Africa
Pleasure Malope, Molebogeng Ruth Lekalakala-Mokaba, Dumisani Cyril Ngcamu, Halima Said, Ivy Rukasha, Shaheed Vally Omar · 2026
Read Bedaquiline resistance-associated genetic mutations and minimum inhibitory concentrations in drug-resistant tuberculosis clinical isolates from Limpopo province, South Africa by Pleasure Malope, Molebogeng Ruth Lekalakala-Mokaba, Dumisani Cyril Ngcamu, Halima Said, Ivy Rukasha, Shaheed Vally Omar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13233694.txt.
Description
Pleasure Malope and five co-authors studied drug resistance in tuberculosis samples from Limpopo, South Africa, in a 2026 paper. The drug in focus, bedaquiline, is key for treating hard forms of TB. Resistance to it threatens control efforts in a country with a heavy load of such cases.
The team tested 147 samples from patients whose TB already resisted other drugs. Most samples were still killed by a low dose, but about thirteen percent needed more. Reading the full gene code showed changes in one gene lay behind most resistance, with two other genes playing smaller roles. The authors say linking dose tests with gene reads can guide care and track spread.
Catalog record
| CREATOR | Pleasure Malope, Molebogeng Ruth Lekalakala-Mokaba, Dumisani Cyril Ngcamu, Halima Said, Ivy Rukasha, Shaheed Vally Omar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |